Why the study?
What is the prevalence of anti-HAV antibody in HIV-positive persons compared to HIV-negative controls, and how does it vary by route of HIV exposure?
Population
4,161 individuals in Taiwan, comprising 1,580 HIV-positive persons seeking medical attention and 2,581…
Design
Cross-sectional
Authors
Loading...
Higher anti-HAV seroprevalence in HIV-positive persons may support targeted vaccination; leaves open whether strategies vary by exposure route.
What is the prevalence of anti-HAV antibody in HIV-positive persons compared to HIV-negative controls, and how does it vary by route of HIV exposure?
HIV-positive individuals, particularly injecting drug users, have a significantly higher prevalence of anti-HAV antibodies, suggesting that targeted HAV vaccination strategies should vary by route of HIV exposure.
Sun et al. (2009) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: